AI in Diagnostics Market to Reach USD 14.3 Billion by 2035, Driven by Healthcare Digitalization

According to the MarketGenics report, the global AI in diagnostics market is likely to grow from USD 2.6 Billion in 2025 to USD 14.3 Billion in 2035 at a highest CAGR of 18.6% during the time period. AI in Diagnostics market is rapidly changing the nature of healthcare, where artificial intelligence is applied to enhance disease detection, diagnosis, and patient management in the fields of radiology, pathology, genomics, and laboratory testing. The AIs allow medical information to be interpreted quicker and more precisely, workflow optimized, and predictive analysis, which can help to intervene early and provide treatment to individuals.

The most popular segment is radiology because of AI-assisted imaging applications, but pathology and genomics are also now adopting AI to process tissues and interpret complicated genetic information automatically. The major growth enablers are the growing need of early and accurate diagnosis, the growing R&D efforts of healthcare and technology firms, and the embrace and use of platform-based solutions like Philips HealthSuite Digital Platform and AI-driven devices offered by GE HealthCare. North America is a leading part with well-established health care infrastructure, regulations, and the level of technology uptake. Predictive diagnostics, cloud-based platforms and strategic alliances are among the market trends that can be used to speed up AI implementation, but issues like regulatory compliance, privacy of data and integrating AI into clinical work processes still exist.

Get the Detailed Industry Analysis (including the Table of Contents, List of Figures, and List of Tables) - from the AI in Diagnostics Market Research Report: https://marketgenics.co/press-releases/ai-in-diagnostics-market-84027

Key Driver, Restraint, and Growth Opportunity Shaping the Global AI in Diagnostics Market

The development of telemedicine and digital healthcare platforms contributes to the AI in diagnostics market as it allows analyzing medical images, lab tests, and genomic data remotely to provide faster and accurate care. An example is the use of AI in Philips HealthSuite Digital Platform, which is used to aid in virtual patient monitoring and diagnostics within healthcare networks.

Lack of standard data formats, communication protocols and integration frameworks across health care systems discourage the expansion of AI in the diagnostics market. Artificial intelligence (AI) technologies tend to have difficulties accessing and processing data across various electronic health records (EHR) systems, imaging machines, and lab systems and are less efficient and accurate. Such disintegration may slow down the process of clinical decision-making and impede the implementation of AI solutions in large scale.

The increased use of platform-based AI solutions is an opportunity to unite diagnostic tools in the healthcare systems, facilitate remote patient monitoring, and provide telemedicine services. These systems make accessibility easier, minimize and speed up diagnostic delays, and enable clinicians to make faster and more data-driven decisions. An example is Cedars-Sinab Connect (CS Connect), an AI-based virtual care assistant designed together with digital health company K Health. Released in 2023, CS Connect is an automated patient intake, symptom evaluation, and treatment recommendation system based on a chatbot interface.

To know more about the AI in Diagnostics Market - Download our Sample Report: https://marketgenics.co/download-report-sample/ai-in-diagnostics-market-84027

Regional Analysis of Global AI in Diagnostics Market

The AI in Diagnostics market is most demanded in North America due to the combination of robust healthcare infrastructure, high levels of technology adoption, and favorable regulatory systems, which provide a perfect environment in which AI-based diagnostic systems can thrive. Hospitals and clinics are integrating AI to conduct imaging, lab and genomic analysis, and telemedicine and remote monitoring are further increasing access to care, which drives the demand. Remarkable examples are Philips HealthSuite Digital Platform, which allows remote diagnostics and predictive analytics powered by AI over healthcare networks, and GE HealthCare AI-enabled radiology equipment, used to simplify radiology and enhance the precision of the diagnosis. These examples show that the progressive ecosystem in North America is a stimulus to AI diagnostics adoption and innovation.

The fastest growth is predicted in the AI of diagnostics of the Asia Pacific market because of the fast modernization of the scientific facilities, the development of the pharmaceutical research and development and the increase in investments on the high-tech AI platform on the medical care and diagnostics. China and other countries like Japan and India are also improving by investing in digital healthcare infrastructure, AI research and regulatory frameworks that can support innovative diagnostic solutions. As an instance, in 2025, AIIMS Patna, together with the Ministry of Health and Family Welfare in India, implemented AI-powered imaging devices to facilitate the diagnostics of cancer, heart, and neurological diseases, making it more accurate and efficient in terms of X-rays, MRI, and CT scans.

Prominent players operating in the global AI in diagnostics market are Aidoc Medical Ltd., Arterys Inc., Butterfly Network, Inc., Enlitic, Inc., Freenome Holdings, Inc., GE Healthcare, Google Health, HeartFlow, Inc., IBM Watson Health, iCAD, Inc., Intel Corporation, Lunit Inc., Microsoft Healthcare, NVIDIA Corporation, Paige.AI, PathAI, Inc., Philips Healthcare, Qure.ai, RADLogics, Inc., Siemens Healthineers AG, Tempus Labs, Inc., Viz.ai, Inc., Zebra Medical Vision, and and Other Key Players.

Buy Now: https://marketgenics.co/buy/ai-in-diagnostics-market-84027

Recent Development and Strategic Overview:

In March 2025, the AI platform of Enlitic and the Edison AI platform of GE HealthCare simplify medical imaging using deep learning, improving the diagnostic process, improving the identification of anomalies faster, and allowing hospitals to implement intelligent and automated medical imaging workflows.

In August 2025, Freenome sold its AI/ML-powered blood-based colorectal cancer test to Exact Sciences in a valuation of up to $885M, using multiomic analysis of 48,995 patients to predict 81% of CRC with 90% specificity, and AI models will be further trained to detect many cancers using real-world data, which might be approved by the FDA and launched commercially in 2026.

Get a preview of our AI in Diagnostics Market Playbook - your guide to GTM strategy, competitive intelligence, supplier dynamics, and Consumer Behavior Analysis: https://marketgenics.co/playbook/ai-in-diagnostics-market-84027

Key Trend: Increasing Demand for AI in In Vitro Diagnostics (IVD)

The growth of AI in Diagnostics market is also fueled by the implementation of AI in In Vitro Diagnostics (IVD) that enhances the accuracy of the diagnosis process, optimizes the laboratory workflow and provides quicker and more reliable test outcomes. As an instance, Diagnostics.ai introduced PCR.AI, an open AI-based program of real-time PCR diagnostics. In contrast to conventional black-box models, the results provided by PCR.AI are traceable and interpretable, allowing it to conduct regulatory-compliant testing and improving the trust of clinicians and the efficiency of diagnostic outcomes.

AI algorithms are capable of processing large volumes of patient data on blood, urine, or tissue samples to identify patterns and anomalies that might otherwise have gone unidentified by human analysis, enhancing early disease diagnosis and planning individual treatment decisions. As an instance, in May 2025, SGPGIMS installed a Beckman Coulter automated lab which can process 4,000+ tests/hour and simplify the processing and testing of samples. Regular diagnostic tests such as liver, kidney, thyroid, blood glucose, now are provided in an hour, which are more accurate, less error prone, and allow quicker clinical decisions.

Innovations demonstrate that AI-powered IVD systems are enhancing the speed of diagnosis and its quality and are changing patient care and driving expansion in the AI in Diagnostics market.

Contact:

Mr. Debashish Roy

MarketGenics India Pvt. Ltd.

800 N King Street, Suite 304 #4208, Wilmington, DE 19801, United States

USA: +1 (302) 303-2617

Email: sales@marketgenics.co

Website: https://marketgenics.co

About Us

MarketGenics is a global market research and management consulting company empowering decision makers across healthcare, technology, and policy domains. Our mission is to deliver granular market intelligence combined with strategic foresight to accelerate sustainable growth.

We support clients across strategy development, product innovation, healthcare infrastructure, and digital transformation.

This release was published on openPR.